Nurix Therapeutics (NRIX) Competitors $9.76 -1.10 (-10.13%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$9.69 -0.07 (-0.72%) As of 10/10/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. OGN, MOR, KNSA, HCM, TARS, BEAM, CDTX, CPRX, MLYS, and ALVOShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Organon & Co. (OGN), MorphoSys (MOR), Kiniksa Pharmaceuticals International (KNSA), HUTCHMED (HCM), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Mineralys Therapeutics (MLYS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Organon & Co. MorphoSys Kiniksa Pharmaceuticals International HUTCHMED Tarsus Pharmaceuticals Beam Therapeutics Cidara Therapeutics Catalyst Pharmaceuticals Mineralys Therapeutics Alvotech Organon & Co. (NYSE:OGN) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Is OGN or NRIX more profitable? Organon & Co. has a net margin of 11.15% compared to Nurix Therapeutics' net margin of -292.50%. Organon & Co.'s return on equity of 163.88% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.15% 163.88% 6.99% Nurix Therapeutics -292.50%-50.45%-39.15% Which has more volatility & risk, OGN or NRIX? Organon & Co. has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. Do analysts recommend OGN or NRIX? Organon & Co. currently has a consensus price target of $17.33, indicating a potential upside of 81.12%. Nurix Therapeutics has a consensus price target of $28.14, indicating a potential upside of 188.35%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Nurix Therapeutics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Does the media prefer OGN or NRIX? In the previous week, Nurix Therapeutics had 13 more articles in the media than Organon & Co.. MarketBeat recorded 17 mentions for Nurix Therapeutics and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.53 beat Nurix Therapeutics' score of -0.21 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in OGN or NRIX? 77.4% of Organon & Co. shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, OGN or NRIX? Organon & Co. has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.39$864M$2.693.56Nurix Therapeutics$54.55M13.68-$193.57M-$2.61-3.74 SummaryOrganon & Co. beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$830.24M$3.38B$6.10B$10.61BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-3.2922.2585.9726.57Price / Sales13.68464.03612.14131.72Price / CashN/A47.2238.5062.09Price / Book1.3110.2112.756.53Net Income-$193.57M-$52.40M$3.31B$276.43M7 Day Performance4.05%0.86%0.80%-0.88%1 Month Performance6.09%10.39%6.21%3.55%1 Year Performance-58.70%27.24%80.34%37.91% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics1.6815 of 5 stars$9.76-10.1%$28.14+188.3%-55.4%$830.24M$54.55M-3.29300Trending NewsEarnings ReportAnalyst ForecastOGNOrganon & Co.4.7971 of 5 stars$10.84-1.5%$17.33+59.9%-46.8%$2.86B$6.40B4.034,000Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KNSAKiniksa Pharmaceuticals International3.633 of 5 stars$38.29-0.5%$44.29+15.7%+48.6%$2.85B$423.24M957.49220News CoverageAnalyst ForecastHCMHUTCHMED2.4986 of 5 stars$16.21+0.7%$20.88+28.8%-24.3%$2.81B$602.20M0.001,811News CoverageAnalyst ForecastTARSTarsus Pharmaceuticals0.688 of 5 stars$67.71+3.9%$66.67-1.5%+97.6%$2.75B$182.95M-29.0650Analyst ForecastGap UpBEAMBeam Therapeutics3.0823 of 5 stars$25.89+0.5%$46.40+79.2%+14.3%$2.60B$63.52M-5.75510News CoverageAnalyst ForecastGap UpCDTXCidara Therapeutics4.0448 of 5 stars$96.45-5.4%$122.29+26.8%+974.6%$2.59BN/A-8.6790Trending NewsAnalyst ForecastGap UpCPRXCatalyst Pharmaceuticals4.7747 of 5 stars$20.73-0.5%$33.20+60.2%+2.3%$2.55B$558.50M12.5680Analyst ForecastBuyback AnnouncementMLYSMineralys Therapeutics1.7753 of 5 stars$38.01-0.1%$43.50+14.4%+214.2%$2.52BN/A-10.6828Analyst ForecastALVOAlvotech3.3096 of 5 stars$8.58+3.1%$14.00+63.2%-35.9%$2.51B$491.98M37.301,032Analyst Forecast Related Companies and Tools Related Companies OGN Alternatives MOR Alternatives KNSA Alternatives HCM Alternatives TARS Alternatives BEAM Alternatives CDTX Alternatives CPRX Alternatives MLYS Alternatives ALVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
